BlossomHill Therapeutics (NASDAQ:BLSM) Director Orbimed Advisors Llc Acquires 625,000 Shares of Stock

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Director Orbimed Advisors Llc purchased 625,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the purchase, the director owned 2,714,279 shares in the company, valued at approximately $43,428,464. The trade was a 29.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

BlossomHill Therapeutics Price Performance

NASDAQ BLSM opened at $16.24 on Thursday. BlossomHill Therapeutics, Inc. has a twelve month low of $15.25 and a twelve month high of $17.25.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.